Tilray's Insider Buying Spree Meets a Wall Street Reality Check
Published on 08/06/2026 at 18:23 | Redaktion boerse-global.de
Two of Tilray Brands' top executives have put their own money on the line, snapping up shares just as the cannabis and beverage company's latest earnings report laid bare the widening gap between its revenue engine and its profitability struggles.
Chief Financial Officer Carl Merton acquired 10,000 shares on Tuesday at an average price of $4.62, a transaction worth $46,200. The purchase came one day after Chief Strategy Officer Denise Faltischek bought 2,500 shares at $4.78, lifting her direct holdings to 141,285 shares. Both moves were disclosed in Form 4 filings with the U.S. Securities and Exchange Commission.
Record Revenue, Familiar Losses
The insider activity follows a fiscal 2026 that Tilray management has framed as the strongest in company history. Revenue for the twelve-month period came in at more than $915 million — the precise figure being $915.5 million, representing an 11 percent increase over the prior year. The fourth quarter alone generated $281.71 million in sales, comfortably beating the consensus estimate of $246.30 million.
That is where the good news on the earnings front ends. The company still posted a net loss of $49.57 million for the quarter, translating to a loss per share of $0.43 against analyst expectations of just minus $0.01. For the full year, the net loss totaled $121.4 million. The pattern is unmistakable: Tilray can grow its top line, but converting that growth into bottom-line profitability remains elusive.
Should investors sell immediately? Or is it worth buying Tilray?
The balance sheet, however, tells a more encouraging story. Net debt has been whittled down to just $0.7 million, while cash and marketable securities stand at roughly $235 million. Management has guided for adjusted EBITDA between $68 million and $75 million in the current fiscal year 2027.
Wall Street Splits on the Outlook
The analyst community has responded to the mixed results with anything but unanimity. TD Securities upgraded the stock from "Buy" to "Strong Buy" on August 1, while a consensus of eight analysts has trimmed the average price target by 11 percent to $8.47 from a previous $9.55. Jefferies cut its target to $19, and TD Cowen lowered its mark from $7 to $5 — both still well above the current Nasdaq price of $4.43, suggesting those firms see meaningful upside despite the near-term earnings drag.
The market's initial reaction to the numbers was decidedly cooler. The Nasdaq-listed shares fell 4.63 percent on the day to $4.43. The Toronto Stock Exchange listing has shown more resilience, closing at C$6.23 on Wednesday after a 4.59 percent decline, though the stock has still managed a 5.77 percent gain over the past seven trading sessions. The monthly picture shows a modest 1.96 percent advance, with the RSI at 51.0 indicating neutral momentum. The annualized 30-day volatility of 48.10 percent, however, underscores just how turbulent this equity remains.
Tilray's market capitalization stands at approximately €533.41 million — a figure that captures the disconnect between the company's operational scale and its subdued valuation.
Beverage Push Continues
Amid the financial noise, Tilray has kept its product pipeline moving. On Thursday, the company launched Mollo Lite Blackberry Lemon Seltzer in Canada, a four-pack of 355-milliliter cans each containing 2.5 milligrams of THC and 5 milligrams of CBG. The pack totals 10 milligrams of THC and 20 milligrams of CBG, marking the first light-THC multi-pack from the Mollo brand and the first such offering in Canada. The product is initially available through licensed retailers in select Canadian markets.
Tilray at a turning point? This analysis reveals what investors need to know now.
The beverage push extends beyond cannabis-infused drinks. Late July saw the introduction of "ZONNA," a smoke-free THC pouch line, while the Revolver Beer and Spirits subsidiary rolled out a new spirits range featuring whiskey, gin, and vodka in Texas. BrewDog, the brewery arm, launched a £1 million promotional campaign with Tilray targeting football fans in the UK and Ireland back in mid-July — evidence of how central the drinks division has become to the company's diversification strategy.
Regulatory Clock Ticking
The broader sector continues to watch the U.S. Drug Enforcement Administration's potential rescheduling of marijuana to Schedule III. The deadline for parties to file supplemental briefs and corrections to the hearing transcript falls on August 17. A favorable decision could shift the valuation landscape for U.S. cannabis names significantly.
For Tilray shareholders, the immediate focus now shifts to October 8, when the company is scheduled to report first-quarter results for fiscal 2027. Between now and then, the question hanging over the stock is whether the insider purchases by Merton and Faltischek prove to be an early indicator of stabilization — or whether the persistent gap between revenue growth and earnings quality continues to weigh on the shares.
Ad
Tilray Stock: New Analysis - 6 August
Fresh Tilray information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
